COMIRNATY
Biological
BioNTech SE
Total Payments
$2.3B
Transactions
73,225
Doctors
24,414
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $199.5M | 5,047 | 2,703 |
| 2023 | $430.5M | 52,344 | 22,055 |
| 2022 | $886.2M | 6,860 | 299 |
| 2021 | $763.7M | 8,974 | 21 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Royalty or License | $1.8B | 38 | 78.0% |
| Unspecified | $499.6M | 21,463 | 21.9% |
| Food and Beverage | $843,695 | 51,461 | 0.0% |
| Consulting Fee | $371,981 | 77 | 0.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $261,117 | 107 | 0.0% |
| Travel and Lodging | $59,945 | 73 | 0.0% |
| Honoraria | $15,100 | 6 | 0.0% |
Payments by Type
General
$1.8B
51,762 transactions
Research
$499.6M
21,463 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | PFIZER INC. | $219.4M | 0 |
| PHASE 1 OPENLABEL DOSEFINDING STUDY TO EVALUATE SAFETY TOLERABILITY AND IMMUNOGENICITY AND PHASE 23 PLACEBOCONTROLLED OBSERVERBLINDED SAFETY TOLERABILITY AND IMMUNOGENICITY STUDY OF A SARSCOV2 RNA VACCINE CANDIDATE AGAINST COVID19 IN HEALTHY CHILDREN AND YOUNG ADULTS | PFIZER INC. | $120.6M | 0 |
| A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | PFIZER INC. | $84.4M | 0 |
| A MASTER PHASE 123 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNA BASED VACCINE CANDIDATES IN HEALTHY CHILDREN | PFIZER INC. | $15.2M | 0 |
| AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS | PFIZER INC. | $13.7M | 0 |
| BNT162-17 | BioNTech SE | $9.0M | 0 |
| A PHASE 23 PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED VACCINE CANDIDATES FOR SARSCOV2 NEW VARIANTS IN HEALTHY INDIVIDUALS | PFIZER INC. | $8.5M | 0 |
| A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE PRODUCTION LOTS AND DOSE LEVELS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PARTICIPANTS 12 THROUGH 50YEARS OF AGE AND THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BNT162B2 RNABASED COVID19 VACCINE CANDIDATES AS A BOOSTER DOSE IN HEALTHY PARTICIPANTS 18 THROUGH 50YEARS OF AGE | PFIZER INC. | $7.6M | 0 |
| A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER | PFIZER INC. | $5.6M | 0 |
| A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE | PFIZER INC. | $3.9M | 0 |
| LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AGE | PFIZER INC. | $2.7M | 0 |
| BNT162-21 | BioNTech SE | $2.5M | 0 |
| DETERMINING RSV BURDEN AND OUTCOMES IN PREGNANT WOMEN AND OLDER ADULTS 60 YEARS OF AGE REQUIRING HOSPITALIZATION | PFIZER INC. | $1.4M | 0 |
| A PHASE 2B OPENLABEL STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF VACCINE CANDIDATE BNT162B2 IN IMMUNOCOMPROMISED PARTICIPANTS 2 YEARS OF AGE | PFIZER INC. | $1.2M | 0 |
| A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS | Pfizer Inc. | $1.1M | 0 |
| A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 | Pfizer Inc. | $864,001 | 0 |
| COMIRNATY | BioNTech SE | $651,777 | 0 |
| PRE CLINICAL | PFIZER INC. | $280,800 | 0 |
| ASSESSMENT AND VALIDATION OF SEVERE COVID19 ILLNESS ENDPOINTS SUPPORT FOR A REALWORLD REGULATORY STUDY TO CONTEXTUALIZE FINDINGS FROM A CLINICAL TRIAL FOR PFIZER BNT162 SARSCOV2 VACCINE CANDIDATE | PFIZER INC. | $179,618 | 0 |
| A MASTER PROTOCOL TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B2 RNABASED VACCINE CANDIDATES IN HEALTHY INFANTS AND CHILDREN | PFIZER INC. | $146,107 | 0 |
Top Doctors Receiving Payments for COMIRNATY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Joseph Eiden | — | Lewes, DE | $2.3B | 21,399 |
| , MD | Pediatric Infectious Diseases | Chapel Hill, NC | $57,063 | 16 |
| , MD | Internal Medicine | Syracuse, NY | $55,851 | 18 |
| , MD | Infectious Disease | Saint Louis, MO | $55,213 | 18 |
| , MD | Pediatric Infectious Diseases | Cincinnati, OH | $40,950 | 12 |
| , M.D | Pediatric Infectious Diseases | New York, NY | $30,450 | 10 |
| , RN, MSN, PHD | Family | Louisville, KY | $24,022 | 35 |
| , M.D | Internal Medicine | Baltimore, MD | $21,560 | 10 |
| , M.D | Maternal & Fetal Medicine | New Haven, CT | $17,500 | 4 |
| , M.D | Pediatrics | Durham, NC | $16,420 | 9 |
| , M.D | Internal Medicine | Baltimore, MD | $15,100 | 10 |
| , MD | Infectious Disease | Louisville, KY | $14,784 | 5 |
| , M.D | Specialist | Saint Louis, MO | $13,500 | 5 |
| , D.O | Infectious Disease | Wynnewood, PA | $13,377 | 12 |
| Tamara Gordon | Dentist | Washington, DC | $12,757 | 6 |
| , MD | Geriatric Medicine | Providence, RI | $11,878 | 3 |
| , M.D | Internal Medicine | Cincinnati, OH | $11,660 | 6 |
| , D.O | Emergency Medicine | Flushing, NY | $11,100 | 1 |
| , MD | Pediatrics | Oakland, CA | $11,000 | 4 |
| , MD | Family Medicine | Buffalo, NY | $10,300 | 4 |
| , MD | Internal Medicine | Sacramento, CA | $9,552 | 13 |
| , MD | Pediatric Infectious Diseases | Aurora, CO | $9,530 | 5 |
| , MD | Pediatrics | Cleveland, OH | $9,070 | 5 |
| , M.D | Pediatrics | Providence, RI | $9,012 | 11 |
| , MD | Pediatric Infectious Diseases | Little Rock, AR | $8,953 | 9 |
Ad
Manufacturing Companies
- BioNTech SE $1.8B
- PFIZER INC. $487.0M
- Pfizer Inc. $2.0M
- PFIZER INTERNATIONAL LLC $79,060
Product Information
- Type Biological
- Total Payments $2.3B
- Total Doctors 24,414
- Transactions 73,225
About COMIRNATY
COMIRNATY is a biological associated with $2.3B in payments to 24,414 healthcare providers, recorded across 73,225 transactions in the CMS Open Payments database. The primary manufacturer is BioNTech SE.
Payment data is available from 2021 to 2024. In 2024, $199.5M was paid across 5,047 transactions to 2,703 doctors.
The most common payment nature for COMIRNATY is "Royalty or License" ($1.8B, 78.0% of total).
COMIRNATY is associated with 20 research studies, including "A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS" ($219.4M).